Lasa Supergenerics Limited (LASA) fair value: what the stock is really worth
As of Sep 28, 2026: fair value of Lasa Supergenerics Limited ₹3.92, price ₹5.60, upside -30.0%, quality 28 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Lasa Supergenerics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹5.60 – ₹87.09 · fair‑value band ₹2.93 – ₹5.85 · the ₹5.60 price screens above the ₹3.92 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow Lasa Supergenerics in your weekly email
Every Wednesday you see whether Lasa Supergenerics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India.
Show more
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide. In addition, it exports its products. Lasa Supergenerics Limited was incorporated in 2016 and is based in Ratnagiri, India.
Stock analysis
Lasa Supergenerics Limited (LASA) currently trades at ₹5.60, while our model-based Fair Value estimate is ₹3.92, implying the stock looks roughly 42.9% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: ₹2.93 (bear) to ₹5.85 (bull), the price of ₹5.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Lasa Supergenerics Limited reported revenue of ₹251M in FY2026 versus ₹1.4B in FY2022, a compound −34.6%/yr. Reported net income was −₹341M in FY2026.
Key figures
Market cap ₹372M (≈ $3.9M) · P/S ratio 1.47 · EPS (TTM) ₹−6.80 · Net margin −136% · Return on equity −51.1% · Return on assets (EBIT) −8.3% · Operating margin 3,728% · Revenue (TTM) ₹253M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −30%, LASA screens richer than that median.
Fair Value models
Bear ₹2.93Fair Value ₹3.92Bull ₹5.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−82.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−42.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.1%
Start year 2021 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
15.5% (2021) → −53.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Compare Lasa Supergenerics Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 624 stocks
Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score30 · Bottom 25%
Fair Value upside−30.0% · Below median
Profitability
Return on assets−9.8% · Bottom 25%
Net margin (TTM)−134.5% · Bottom 25%
Growth and dividend
Revenue growth−93.3% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 16
FUTURE (revenue growth)0· sector 18
PAST (return on equity)0· sector 26
HEALTH (low debt)100· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Lasa Supergenerics Limited (LASA) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹3.92 versus a price of ₹5.60, about −30% upside (overvalued).
What is the fair value of LASA?
Our model-based fair value for Lasa Supergenerics Limited is ₹3.92 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹5.60.
What is the quality score of LASA?
Lasa Supergenerics Limited has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lasa Supergenerics Limited (LASA)?
Our model-based price target is the fair value of ₹3.92 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario ₹2.93, optimistic scenario ₹5.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Lasa Supergenerics Limited stock forecast for 2026?
Our models put fair value at ₹3.92, about −30% upside versus a price of ₹5.60 (overvalued). Cautious scenario ₹2.93, optimistic scenario ₹5.85. The calculation is refreshed regularly with new filings.
What is the revenue of Lasa Supergenerics Limited (LASA)?
Lasa Supergenerics Limited reported trailing-twelve-month revenue of about ₹253M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Lasa Supergenerics Limited (LASA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lasa Supergenerics Limited it is ₹3.92 per share (as of Sep 27, 2026), against a price of ₹5.60. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lasa Supergenerics Limited stock overvalued or undervalued in 2026?
As of Sep 27, 2026, LASA trades above its calculated fair value: price ₹5.60, fair value ₹3.92, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LASA?
No. The price is what the market pays today (₹5.60); the fair value is what the company's own numbers justify (₹3.92). For Lasa Supergenerics Limited the two are ₹1.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lasa Supergenerics Limited worth?
The market values Lasa Supergenerics Limited at about ₹372M (market capitalisation, as of Sep 27, 2026). Per share that is ₹5.60; our models calculate a fair value of ₹3.92 per share.
What do the bullish and bearish scenarios say about LASA?
Our models span a range for Lasa Supergenerics Limited: cautious scenario ₹2.93, base ₹3.92, optimistic ₹5.85 per share (as of Sep 27, 2026, price ₹5.60). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Lasa Supergenerics Limited (LASA)?
Balance-sheet figures for Lasa Supergenerics Limited (as of Sep 27, 2026): return on equity −51.1%. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is LASA from its 52-week high?
Lasa Supergenerics Limited trades at ₹5.60, about 53% below its 52-week high of ₹12.04 and at the low of ₹5.60 (as of Sep 28, 2026). Distance from the high says nothing about value: that is what the fair value of ₹3.92 is for.
Which stocks are comparable to Lasa Supergenerics Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lasa Supergenerics Limited stock attractive at the current price?
The data as of Sep 27, 2026: price ₹5.60, calculated fair value ₹3.92 (−30%), Quality Score 28/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LASA calculated?
We run Lasa Supergenerics Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹3.92, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.9 % above its aggregate fair value. Lasa Supergenerics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lasa Supergenerics Limited (LASA)?
The closing price on Sep 28, 2026 was ₹5.60. Our model-based fair value is ₹3.92, about −30% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lasa Supergenerics Limited right now?
Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (₹2.93 to ₹5.85) leaves room in how you read the outcome.
Key figures of Lasa Supergenerics Limited
How large is the market capitalisation of Lasa Supergenerics Limited (LASA)?
The market capitalisation of Lasa Supergenerics Limited is ₹372M (≈ $3.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lasa Supergenerics Limited (LASA)?
The price-to-sales ratio of Lasa Supergenerics Limited is 1.47 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lasa Supergenerics Limited (LASA)?
Earnings per share at Lasa Supergenerics Limited are ₹−6.80. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lasa Supergenerics Limited (LASA)?
The net margin of Lasa Supergenerics Limited is −136% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lasa Supergenerics Limited (LASA)?
The return on equity (ROE) of Lasa Supergenerics Limited is −51.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lasa Supergenerics Limited (LASA)?
On an EBIT basis the return on assets of Lasa Supergenerics Limited is −8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lasa Supergenerics Limited (LASA)?
The operating margin of Lasa Supergenerics Limited is 3,728% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lasa Supergenerics Limited (LASA)?
Revenue at Lasa Supergenerics Limited is growing −93.3% versus a year earlier (3y avg −42.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lasa Supergenerics Limited (LASA)?
Earnings per share at Lasa Supergenerics Limited are growing +225% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lasa Supergenerics Limited (LASA) generate?
The free cash flow of Lasa Supergenerics Limited is −₹737K (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lasa Supergenerics Limited (LASA) carry?
The net debt of Lasa Supergenerics Limited is ₹90.5M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Lasa Supergenerics Limited in the live analysis
One click puts Lasa Supergenerics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
